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with interest, noticing reference in their discussion to one of our recent publications that appeared in Thrombosis and Haemostasis (2) . However, we would like to correct some significant misinterpretations of our data as cited by the investigators. Indeed, our antibody is referred to as a monoclonal antihuman ADAMTS-13 antibody. This is incorrect. In fact, we have reported on the discovery and characterization of a monoclonal antihuman von Willebrand factor antibody, designated Mab508. This is not only clearly written in the abstract, but our article also describes in detail the epitope within von Willebrand factor that is recognized by this antibody. Describing our antibody as being antihuman ADAMTS-13 is therefore an important oversight.
Second, the investigators suggest that our antibody blocks ADAMTS-13 activity by 83% and that such widespread inhibition may inadvertently provoke a hypercoagulable, thrombotic thrombocy- 
Murugiah et al. (4) examined the United States
Medicare database and reported 30-day and 1-year mortality rates of 2.5% and 6.9% for patients with principal TTC and 4.7% and 11.4% for patients with secondary TTC, respectively. These results illustrate the indisputable prognostic difference between principal and secondary TTC, which has also been demonstrated previously (5). However, the observed mortality in the overall TTC population is comparable to the aforementioned trials in unselected TTC patients, albeit at the lower end of the reported rates.
Considering these novel insights, we think that the prognosis of TTC should no longer be referred to as favorable for patients with principal TTC. During the acute and subacute phases of the disease, patients are prone to severe complications, including heart failure, cardiogenic shock, or life-threatening
